Author

S. S. Ramalingam

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Approach:deep learning· 2 Approach:statistical model· 2 Research Focus:clustering· 1 Research Focus:differential expression· 1

Frequent Co-Authors

H. Fu· 3 shared W. Zhou· 3 shared A. I. Marcus· 2 shared C.-S. Seong· 2 shared H. Claussen· 2 shared H. R. Johnston· 2 shared J. Koo· 2 shared M. Gilbert-Ross· 2 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

H. Fu

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Live-cell invasive phenotyping uncovers the ALK2/BMP6 iron homeostasis pathway as a therapeutic vulnerability in LKB1-mutant lung cancer

J. Koo, C.-S. Seong, R. E. Parker, B. Dwivedi, R. A. Arthur, A. R. Dinasarapu, H. R. Johnston, H. Claussen, C. Tucker-Burden, S. S. Ramalingam, H. Fu, W. Zhou, A. I. Marcus, M. Gilbert-Ross

This study identifies the ALK2/BMP6 iron homeostasis pathway as a therapeutic target in LKB1-mutant lung cancer using live-cell imaging and transcriptome analysis.

bioRxiv · Jun 14, 2023 · PreprintCancer Biology

Loss of the endocytic tumor suppressor HD-PTP phenocopies LKB1 and promotes RAS-driven oncogenesis.

C.-S. Seong, C. Huang, A. C. Boese, Y. Hou, J. Koo, J. K. Mouw, M. Rupji, G. Joseph, H. R. Johnston, H. Claussen, J. M. Switchenko, M. Behera, M. Churchman, J. M. Kolesar, S. M. Arnold, , M. Gilbert-Ross

The paper shows that loss of HD-PTP, a tumor suppressor, promotes RAS-driven oncogenesis and is associated with adenosquamous lung cancer, suggesting it as a therapeutic target.

bioRxiv · Jan 26, 2023 · PreprintCancer Biology

Systematic discovery of mutation-directed neo-protein-protein interactions in cancer

X. Mo, Q. Niu, A. A. Ivanov, Y. H. Tsang, C. Tang, C. Shu, A. Wahafu, S. Doyle, D. Cicka, X. Yang, D. Fan, M. A. Reyna, L. A. D. Cooper, C. S. Moreno, W. Zhou, , H. Fu

The paper identifies mutation-directed neo-protein-protein interactions in cancer using a high-throughput screening platform, revealing therapeutic opportunities through neo-interaction rewiring.

bioRxiv · Oct 3, 2021Cancer Biology

The CD8+ T cell landscape of human brain metastases

L. J. Sudmeier, K. B. Hoang, E. K. Nduom, A. Wieland, S. G. Neill, M. J. Schniederjan, S. S. Ramalingam, J. J. Olson, R. Ahmed, W. H. Hudson

This study characterizes CD8+ T cell phenotypes and spatial distribution in brain metastases using single-cell RNA-sequencing and spatial transcriptomics, revealing distinct subpopulations and their functional states.

bioRxiv · Aug 3, 2021Immunology